SUMO2 and PML

  • Number of citations of the paper that reports this interaction (PMID 9452416)
  • 43
  • Data Source:
  • HPRD (in vivo)

SUMO2

PML

Gene Name small ubiquitin-like modifier 2 promyelocytic leukemia
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 91 interactors: ALAS1 ARL13A ARNTL ATXN1 ATXN7 AURKB BAD BCL11A BLM BRCC3 BRE C18orf25 CCNE2 CDCA8 CENPC CHAF1A CHD3 CMTM6 CORO2A CSNK2B CUL3 FAM175A FOS HDAC4 HDAC9 HIF1A HIPK2 HNF4A HOMEZ HSF2 JUN KALRN KDM1A KRT14 KRT5 KRT8 LEF1 MAF1 MAST2 MDC1 MSX1 MYB NFKBIA PARP1 PIAS1 PIAS2 PIAS3 PIAS4 PML RAC1 RANGAP1 RB1 RNF111 RNF4 SAE1 SENP1 SENP2 SENP3 SENP5 SENP6 SENP7 SETDB1 SETX SH3KBP1 SLC22A2 SNCA SOX10 SOX6 SP100 STK24 SUMO1 TDG TDP2 TEAD3 TNIP1 TOPORS TP53BP2 TRIM63 UBA2 UBE2I USP25 USPL1 VIM WRN XPC ZBTB1 ZCCHC12 ZCCHC7 ZHX1 ZMYM2 ZMYM5 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9
Entrez ID 6613 5371
HPRD ID 04332 00023
Ensembl ID ENSG00000188612 ENSG00000140464
Uniprot IDs P61956 P29590
PDB IDs 1WM2 1WM3 1WZ0 1Z5Q 2AWT 2CKH 2D07 2IO0 2IO3 2IYD 2RPQ 3UIN 3UIO 1BOR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
augment  consequent  delaying  elusive  emerged  enhance  enhancing  facilitates  fasting  fate  linking  maintenance  melanoma  modifications  modified  node  nutrient  partner  promising  relief  rev1  sensing  short  specialized  starvation  suppressor  therapies  toxic  turn 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Difference) ?
augment  consequent  delaying  elusive  emerged  enhance  enhancing  facilitates  fasting  fate  linking  maintenance  melanoma  modifications  modified  node  nutrient  partner  promising  relief  rev1  sensing  short  specialized  starvation  suppressor  therapies  toxic  turn 
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
Tagcloud (Intersection) ?